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Glomerular fibrinolytic activity in anti-GBM glomeruionephritis in
rabbits. Fibrin is an important mediator of injury in severe proliferative
forms of glomerulonephritis (GN). Normal glomeruli express fibrino-
lytic activity, which may protect against the injurious effects of fibnn
deposition. Changes in glomerular fibrinolytic activity (GFA) may play
an important role in modulating fibrin accumulation in ON. To study the
changes in GFA associated with fibrin deposition in ON, autologous
phase anti-glomerular basement antibody initiated ON (anti-GBM GN)
was studied in rabbits. Net OFA was significantly reduced in associa-
tion with glomerular fibrin deposition (1.3 0.8 ng fibrin lysed/103
glomerulil2 hr, normal 57.1 25.4 ng fibrin lysedJlO3 glomeruli/2 hr, P
< 0.02). Reduced OFA in fibrin associated GN was associated with
decreased expression of tissue type plasminogen activator (tPA) and
increased expression of plasminogen activator inhibitor type-I (PAl-I)
and glomerular macrophage infiltration. In a fibrin independent model
of anti-OBM induced ON (heterologous phase), with equivalent injury
(proteinuria), net GFA was increased (174 64 ng fibrin IysedIlO3
glomerulil2 hr). This was associated with increased tPA and uPA, and
decreased PAL-I in the absence of significant macrophage infiltration.
These studies demonstrate that fibrin deposition in GN is associated
with a net reduction of GFA, attributable to reduced expression of
plasminogen activators and augmentation of PAL-I. Reduction of OFA
may potentiate glomerular fibnn deposition and consequent glomerular
injury. The association between glomerular macrophage influx and
reduction in GFA suggests that this change may be directed by
macrophages.
Fibrin is a prominent glomerular participant in aggressive
proliferative and crescentic human glomerulonephntis (GN)
[1—3]. In experimental GN, induced by either chronic immune
complex disease [4] or anti-GBM antibodies [5], glomerular
injury is similarly associated with crescentic ON and renal
failure. The important role played by glomerular fibrin deposi-
tion has been best demonstrated by observing the beneficial
effects associated with defibrination in these rabbit models of
ON where crescent formation and renal failure were substan-
tially prevented [4, 5].
Recent studies have suggested an important role for macro-
phages as initiators of glomerular fibrin deposition in ON by
their enhanced expression of tissue factor. In patients with
crescentic ON, a close association has been observed between
glomerular injury, fibrin deposition, macrophage accumulation
and increased tissue factor expression [6]. Isolation of glomeruli
from patients with these glomerular findings have shown vastly
augmented expression of glomerular procoagulant activity
(PCA) [7]. Similar observations have been made in experimen-
tal crescentic ON in rabbits induced by anti-GBM antibodies
(autologous phase). Glomerular injury in this situation is asso-
ciated with glomerular influx of macrophages and their local
activation to enhance PCA expression [8—10]. This is closely
associated with the initiation of glomenilar fibrin deposition.
Macrophage depletion and repletion studies confirm the impor-
tant role of infiltrating macrophages in glomerular procoagulant
enhancement and fibrin deposition [10]. Thus, this model dem-
onstrates very similar events to those occurring in human
crescentic GN and studies of the mechanisms of fibrin deposi-
tion are likely to be relevant to humans.
The role of fibrinolytic molecules in fibrin deposition in GN is
not clear. The potential for the fibrinolytic system to play a
protective role is again highlighted by studies in anti-GBM GN
in rabbits showing benefit from treatment with pharmacological
doses of tissue plasminogen activator [11] or streptokinase [12].
Use of antifibrinolytic agents, both in humans [13] and experi-
mental GN [14], has been demonstrated to enhance glomerular
fibrin deposition.
We have therefore sought to characterize the presence and
nature of glomerular fibrinolytic activity (GFA) in normal rabbit
glomeruli, and to study the changes observed in the relevant
and otherwise well-characterized model of anti-GBM antibody-
induced crescentic GN in rabbits.
Methods
Animals
Male New Zealand White rabbits weighing 1.8 to 2.5 kg were
used in these experiments.
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Preparation of heterologous anti-GBM globulin
Horse anti-rabbit GBM antibody was prepared by repeated
immunization of a horse with purified particulate rabbit GBM in
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phosphate buffered saline (PBS). The horse serum was exten-
sively absorbed against rabbit platelets, leukocytes and eryth-
rocytes, and a globulin fraction was prepared by precipitation
with ammonium sulphate at a final concentration of 50%.
Experimental models
Two models of anti-GBM antibody initiated GN were stud-
ied.
Autologous phase anti-GBM antibody initiated GN. Autolo-
gous phase anti-GBM GN was induced by intravenous admin-
istration of horse anti-rabbit GBM globulin (25 mg/kg) to rabbits
presensitized to horse globulin five days earlier by subcutane-
ous injection of horse globulin (4 mg) in Freund's complete
adjuvant (Commonwealth Serum Laboratories, Parkville, Vic-
toria, Australia). This dose of anti-GBM globulin resulted in a
mean binding of 28.1 2.7 g of specific kidney fixing horse
globulin per gram wet weight of kidney. Injury was assessed 96
hours after administration of anti-GBM globulin. Defibrination
studies have previously demonstrated that the development of
progressive renal impairment and crescents in this model is
fibrin dependent [5, 12, 15].
Heterologous phase anti-GBM antibody initiated GN. Het-
erologous phase anti-GBM GN was initiated in non-sensitized
rabbits by an intravenous dose of horse anti-GBM globulin (45
mg/kg) which bound 40.4 1.8 jsg of specific kidney fixing
horse globulin per gram wet weight of kidney, and produced
immediate proteinuria. Injury in this model was assessed after
24 hours. In this model, significant glomerular fibrin deposition
does not occur [101.
Isolation of glomeruli
Renal cortical tissue was collected aseptically into culture
medium (Eagles Minimal Essential Medium, Commonwealth
Serum Laboratories) containing 10% fetal calf serum (FCS,
Flow Laboratories, North Ryde, NSW, Australia) for prepara-
tion of glomerular conditioned medium or into ice-cold 20 mM
Tris-HCI buffer (pH 7.4 containing 125 mri NaCl, 10 mM KCI,
10 m sodium acetate and 5 m glucose) for preparation of
glomerular lysates.
Preparation of glomerular conditioned medium (supernatants)
Glomeruli were isolated under sterile conditions by a graded
sieving technique [16] to obtain approximately l0 glomeruli.
Contamination with tubular fragments was less than 5% (as
assessed by phase contrast microscopy). Glomeruli were cul-
tured in 75 cm2 polystyrene tissue culture flasks (Sterilin,
Feltham, UK) for 16 hours at 37°C in a 5% C02/air humidified
atmosphere, at a concentration of 5 x i0 glomeruli per ml in
serum-supplemented medium. Conditioned medium was col-
lected and centrifuged at 1600 g for five minutes to remove
glomeruli and the supernatant stored at —70°C.
Preparation of glomerular lysates
Glomeruli were washed and resuspended at a concentration
of 5 x 103/ml in Tris-HCI buffer containing 1 mi CaC12 and
incubated for 30 minutes at 37°C. Glomerular lysates were
prepared by solubilization in 0.1% Triton X-l00 at room tem-
perature for seven minutes, collected after centrifugation at
3000 g for 10 minutes at 4°C and stored at —70°C.
Assessment of glomerular macrophage infiltration
Glomerular macrophages numbers were determined by indi-
vidual droplet culture as previously described [17] and by
immunohistochemical staining with a monoclonal anti-rabbit
macrophage antibody [18] (RAM-li, a gift from Dr. A. Gown,
Seattle, Washington, USA).
Assessment of glomerular injury
Proteinuria. Rabbits were housed in metabolic cages to
collect their urine output over the final 24 hours of each
experiment. Protein concentrations were determined by the
Bradford method [19]. Absorbance of light (595 nm wavelength)
was measured 10 minutes after the addition of 3 ml of 100 sg/ml
Electran Page Blue G90 (BDH Chemicals, Poole, UK) in 5%
ethanoll8. 1% orthophosphoric acid to 20 d of each urine
sample. Values were calculated from a standard curve derived
from bovine serum albumin, (BSA, Miles Inc., Kankakee,
Illinois, USA).
Histology. Kidney tissue was fixed in Bouin's fixative and
stained with periodic acid-Schiff reagent to assess light micro-
scopic appearances. Tissue for immunofluorescence (IF) was
frozen in liquid nitrogen, then stored at —70°C. Six micrometer
cryostat sections were stained with goat anti-rabbit fibrinogen
(Research Plus Laboratories, Bayonne, New Jersey, USA), to
assess glomerular fibnn deposition.
Measurement of net glomerular fibrinolytic activity
A solid phase 125! fibrin lysis assay based on the assay of
Moroz and Gilmore [20] was used to measure the net plasmin-
ogen dependent GFA.
Rabbit fibrinogen (Sigma Chemical Company, St. Louis,
Missouri, USA) was radiolabeled by a modified chloramine T
method and extensively dialyzed against PBS. The 125! activity
was determined to be 97% protein bound after precipitation
with trichloroacetic acid, and more than 80% of the radiolabeled
fibrinogen was clottable upon the addition of thrombin (Armour
Pharmaceutical Company, Kankakee, Illinois, USA). Trace
labeled fibrinogen (0.5 mg/mI in 0.015 M phosphate buffer, pH
8.2) of known specific activity was absorbed to 96-well U
bottom polystyrene plates (Disposable Products, Adelaide,
Australia) by incubation for three hours at 37°C. The plates
were washed three times in 0.05 M Tris-HC1 buffer (pH 8.2,
containing 0.1 M NaC1) and treated with thrombin (10 U/mi in
0.16 M NaCl) for 15 minutes at 37°C to generate a fibrin matrix.
After three washings, the plates were stored at 4°C for a
maximum of seven days with 0.05 M Tris HC1 buffer. The mean
binding of fibrinogen to the plates was 1.8 0.25 sg/well.
Glomerular supernatants (60 1.d) were incubated in fibrin
coated wells, for two hours at 37°C in the presence or absence
of rabbit plasminogen (0.025 casein units, Sigma) as previously
described [21]. The 1251 activity released into the soluble phase
was used to determine the quantity of fibrin lysed from the
specific activity of the clottable fibrinogen used to coat the
plates. The difference between fibnn lysis in the presence and
absence of plasminogen was used to determine the plasminogen
dependent fibrinolytic activity of the glomerular supernatants,
and the results expressed as ng fibrin lysed per i0 glomeruli per
two hours (ng fibrin/103 gloms/2 hr). All samples were assayed
in triplicate.
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Detection and identification of plasminogen activators by
fibrin autography
Fibrin autography, performed using standard techniques [221,
was used to detect plasminogen activator activity in glomerular
supernatants and lysates. Supernatants, human urokinase plas-
minogen activator (uPA; American Diagnostica, Greenwich,
Connecticut, USA) and human tissue plasminogen activator
(tPA; American Diagnostica) were run in parallel lanes on a
10% SDS polyacrylamide gel, which was then overlaid on a
fibrin agar indicator gel prepared using plasminogen-rich bovine
fibrinogen (Sigma) and bovine thrombin (Armour). The gels
were incubated at 37°C in a humidified atmosphere to reveal
lysis zones corresponding to the presence of plasminogen
activator activity. There was no detectable lytic activity in
serum-supplemented culture medium alone. Equal volumes of
supernatants from glomeruli cultured at a standard concentra-
tion (5 x 103/ml) were added in each lane. Glomerular lysates
and standards were run on separate gels.
Pre-absorption of glomerular supernatants and lysates with
antisera to uPA and tPA was used to determine the antigenic
nature of the plasminogen activators. Supernatants were incu-
bated with goat anti-human uPA antibody (American Diagnos-
tica), goat anti-human tPA antibody (American Diagnostica) or
non-immune goat serum bound to CNBr-activated sepharose
for 24 hours at 4°C. The sepharose beads were removed by
centrifugation and the plasminogen activator activity remaining
was then analyzed by fibrin autography as described.
Quantitation of tPA functional activity
Quantitation of tPA activity in glomerular supernatants and
lysates was performed according to a previously described
method [23, 24]. The high affinity of tPA for a fibrin matrix
bound to polyvinyl chloride microtiter plates was used to
separate plasminogen activator activity of tPA from uPA. Using
this technique, 90 2% of the activity of pure human tPA and
18 2% of pure human uPA bound to the fibrin matrix.
Conversion of plasminogen to plasmin was detected by the
generation of a colored product from a plasmin specific chro-
mogenic substrate (H-D-Nie-HHT-Lys-pNA.2 AcOH, Ameri-
can Diagnostica).
Glomerular supernatants and lysates were diluted with an
equal volume of PBS containing 4mg/mi BSA and 0.01% Tween
20 (PBT buffer). tPA standards were also prepared in serum-
supplemented culture medium or Tris lysate buffer and diluted
in PBT buffer. Both tPA standards and samples (100 l) were
incubated for 75 minutes at 37°C in fibrin coated wells. The
wells were washed three times with PBT buffer, and then
incubated for four hours at 37°C with human glu-type plasmin-
ogen (0.09 mg/mi final concentration, Technoclone, Vienna,
Austria) and chromogenic plasmin substrate at a final concen-
tration of 0.9 m in 100 1d of PBT buffer. The reaction product
(paranitroanalide) was detected by its absorption at 405 nm
using a micro-ELISA reader (Titertek Multiskan; Flow Labo-
ratories). Plates were blanked on a well containing Eagles
medium with 10% FCS or Tris lysate buffer. All standards and
samples were assayed in duplicate. The lower limit of detection
of tPA was less than 0.01 international units/mi (lU/mi). tPA
activity of the standards was calculated from the concentration
using a conversion factor of 1 lU/mi being equivalent to 2 ng/ml
tPA.
Quantitation of uPA functional activity
uPA activity was measured in a functional assay using a uPA
specific chromogenic substrate (Spectrozyme 221, American
Diagnostica). Fifty microliters of glomeruiar supernatant, lysate
or purified human uPA (Ukidan, Serono, Rome, Italy) diluted
with an equal volume of 50 mrt Tris-HCI buffer containing 0.1%
BSA (pH 7.5) was incubated for three hours with 100 1d of 0.5
m substrate in a microtiter plate at room temperature. The
colored product was measured in an ELISA plate reader by its
absorbance at 405 nm. All samples and standards were assayed
in duplicate. Standards were diluted in serum-supplemented
Eagles medium or Tris lysate buffer to provide separate refer-
ence curves for glomerular supernatants and lysates. Activity!
concentration curves were linear in the range 0.2 to 30 lU/mi.
Measurement of tPA antigen
tPA antigen in glomerular supernatants and lysates was
measured by ELISA (Imubind tPA, American Diagnostica).
This assay employs a sandwich technique using a polycional
anti-human tPA antibody which cross reacts with rabbit tPA.
The assay detects both free tPA and tPA compiexed to PAl and
has a lower detection limit of 0.1 ng/ml. Human single chain tPA
was used as a standard in this assay. All standards and samples
were assayed in duplicate.
Detection of plasminogen activator inhibitor by reverse fibrin
autography
The capacity of glomerular supernatants and lysates to inhibit
uPA initiated lysis of a fibrin agar gel was used to detect PA!
activity as described previously [25]. Giomerular supernatants
and recombinant human piasminogen activator inhibitor type 1
(rhPAI-l) (Dr. P. DeCierck, Leuven, Belgium) were run in
parallel lanes in 10% SDS polyacrylamide gel, and then overlaid
on a freshly prepared fibrin indicator gel containing uPA (0.2
lU/mi). The gels were incubated at 37°C in a humid atmosphere,
and bands of fibrin resistant to lysis indicated PA! activity.
Culture medium (containing serum) did not show areas of lysis
inhibiting activity.
Measurement of PAl activity
PAl-i activity was measured using a functional assay by its
capacity to inhibit uPA dependent cleavage of a chromogenic
substrate (Spectrozyme 221) based on a previously described
method [261. Glomerular supernatants, iysates and human cell
line derived PAl- 1 (American Diagnostica) in culture medium or
lysate buffer, were activated by dialysis against 4 M guanidine
HC1 for four hours at 37°C, and were then dialyzed for 16 hours
at 4°C against PBS with 0.01% Tween-80 [27]. uPA (Serono)
was diluted to 4 lU/mI in "activity buffer" containing 50 mM
Tris-HCI, 150 mti NaCi, 0.1% BSA and 0.01% Tween-80.
Samples or PAl- 1 standards (50 p1) were incubated with uPA
(50 p1) in microtiter plates for 20 minutes at 37°C. Chromogenic
substrate (100 p1 of 0.5 mM) was subsequently added and the
generation of colored product was determined by the absorp-
tion at 405 nm after four hours at room temperature. All
standards and samples were run in triplicate.
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Table 1. Proteinuna, glomerular macrophages, glomerular fibrin
deposition (GFD) and glomerular fibrinolytic activity (GFA), in
normal rabbits and rabbits with anti-GBM ON
Proteinuria
mg/24 hr
Olomerular
macrophages
mac/glom
OFD
(0 to + + +)
GFA
ng fibrini
1O glomi
2 hr
Normal
Fibrin
associated
ON
Fibrin
independent
ON
14.9 2.0
1549 262
1567 351
0.3 0.2
63.6 5.8
0.5 0.3
0
+++
0
57,1 25.4
1.3 0.8a
174 64
a P < 0,02 c.f. Normal
Activated human PAl-i produced a dose dependent inhibi-
tion of uPA with a linear relationship on semilog scale in the
range of 1 to 100 ng/ml PA!-! (correlation coefficient 0.98). PAl
activity was calculated from the difference between uPA activ-
ity in culture medium or lysate buffer and the uPA activity in
samples, by reference to a standard curve of uPA activity. PA!
activity is expressed as arbitrary units (aU/105 glom) where I
aU represents the inhibition of 1 IU of uPA activity. In this
assay, 10 ng/ml PAl-i standard in culture medium exhibited
1.28 IU uPA inhibiting activity.
Experimental design and statistics
The following groups of rabbits were studied: (i) normal
rabbits (N = 6); (ii) rabbits with autologous phase anti-OBM
ON on day 4 of disease (N = 6); and (iii) rabbits with
heterologous phase anti-GBM GN (N = 6).
Results are expressed as the mean the standard error of the
mean (5EM) and statistical significance assessed by a two-tailed
Mann Whitney U test.
Results
Autologous phase anti-GBM GN
Rabbits with autologous phase anti-GBM GN (fibrin associ-
ated ON) developed significant proteinuria (1549 262 mg/24
hr, normal 14.8 2.0; P < 0.005) in association with macro-
phage infiltration (63.6 5.8 mac/glom, normal 0.3 0.2
mac/glom) and a proliferative GN with prominent glomerular
fibrin deposition and fibrinous crescents (Table I).
Heterologous phase anti-GBM GN
Rabbits with heterologous phase injury (fibrin independent
ON) developed similar proteinuria (1567 351 mg124 hr) to
rabbits with fibrin-associated autologous phase anti-GBM ON.
Their glomerular lesion was characterized by a proliferative
ON, with prominent neutrophil infiltration, in the absence of
glomerular fibrin deposition. Olomerular macrophage numbers
(0.5 0.3 mac/glom) were not different to macrophage numbers
in normal glomeruli (Table 1).
Net glomerular plasminogen-dependent fibrinolytic activity
(GFA) in GN
GFA in glomerular supernatants from rabbits with fibrin
associated ON (autologous phase anti-GBM GN) was signifi-
cantly reduced (1.3 0.8 ng fibrin/103 gloml2 hr) compared to
supernatants from normal glomeruli (57.1 25.4 ng fibrin/103
glom/2 hr; P < 0.02; Table 1). In glomerular supernatants from
rabbits with fibrin independent GN (heterologous phase anti-
GBM GN), GFA was increased compared to normal 174 64
ng fibrinll03 glomI2 hr).
Demonstration and characterization of glomerular
plasminogen activator activity by fibrin autography
Glomerular supernatants from normal rabbits and rabbits
with fibrin associated and fibrin independent GN showed two
bands of fibnnolytic activity with molecular weights of 110 and
120 kD, suggesting plasminogen activator-plasminogen activa-
tor inhibitor complexes (Fig. 1). Glomerular supernatants from
rabbits with fibrin associated ON produced smaller areas of
lysis (lane Bi) than that produced by the same amount of
glomerular supernatant from normal rabbits (lane Al) or rabbits
with fibrin independent GN (lane Cl). Fibrinolytic activity in
each group was substantially removed by absorption of glomer-
ular supernatants with anti-tPA antibody (lanes A2, B2, C2) and
to a lesser extent by absorption with anti-uPA antibody (lanes
A3, B3, C3).
Glomerular lysates in each of the three groups showed a
single area of lytic activity with a molecular weight of 45 kD
(Fig. 2). Lysates from glomeruli of rabbits with fibrin associated
ON (lane Fl) produced a smaller area of lysis than glomerular
lysates from normal rabbits (lanes Dl) and rabbits with fibrin
independent ON (lanes El). Absorption of lysates with anti-
uPA antibody completely removed the lytic activity (lanes D3,
E3, F3). Absorption with anti-tPA antibody did not affect the
area of lysis activity (lanes D2, E2, F2).
Quantitation of tPA and uPA activity
The predominant plasminogen activator activity in glomeru-
lar supernatants was tPA (Tables 2 and 3). Supernatants from
normal glomeruli contained 8.7 3.7 IU tPA activity/b5 glom
and 6.7 1.3 IU uPA activity/b5 glom. Glomerular superna-
tants from rabbits with fibrin associated GN contained less tPA
activity (0.7 0.5 lU/b5 glom) than normal supernatants (P <
0.08). uPA activity (6.5 1.8 JU/105 glom) was similar to
normal. In fibnn independent ON, tPA activity in glomerular
supernatants (12.9 8.7 lU/tO5 glom) was not significantly
different to normal. uPA activity in glomerular supernatants
(16.8 1.2 JU/105 glom) was significantly increased compared
to normal (P < 0.002).
Olomerular lysates from all three groups contained substan-
tial amounts of uPA activity. There was no significant change in
the uPA activity in glomerular lysates from rabbits with fibrin
independent ON (115 21 lU/b5 glom) and fibrin associated
ON (95 12 lU/to5 glom) and normal rabbits 132 14 lU/tO5
glom). tPA activity was undetectable in glomerular lysates in all
groups.
Glomerular tPA antigen
Normal glomeruli contained 69.4 22.4 ng tPA/b05 glom in
supernatants and 2.9 1.9 ng tPA/105 glom in lysates. Super-
natants from glomeruli of rabbits with fibrin associated ON
showed a reduction in tPA antigen (17.7 11.0 ng/105 glom)
compared to supernatants from normal glomeruli (P < 0.06).
tPA uPA Al A2 A3 Bl B2 B3 Cl C2 C3
115 kD
70 kD
50 kD
30 kD
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Fig. 1. Plasminogen activator activity demonstrated byfibrin autography in glomerular supernatants, (preabsorbed with normal goat serum)from
a normal rabbit (lane Al), a rabbit with autologous phase anti-GBM GN (lane BI) and a rabbit with heterologous phase anti-GBM GN (lane Cl).
The same supernatants were preabsorbed with anti-tPA antibody (lanes A2, B2, C2) or anti-uPA antibody (lanes A3, B3, C3). Pure human tPA and
uPA were run as standards. Molecular weight calibrations are indicated.
tPA antigen in glomerular Lysates from these rabbits (1.7 0.9
ngJlO5 glom) was not significantly reduced compared to normal.
In fibrin independent GN, tPA was not significantly different
from normal in glomerular supernatants (99.0 22.3 ng/105
glom) or lysates (1.5 0.9 ngIlO5 glom).
Demonstration of glomerular plasminogen activator inhibitor
activity by reverse fibrin autography
Glomerular supernatants from normal rabbits exhibited an
area of inhibitor activity similar to that seen with human
recombinant PAl-i (Fig. 3, left hand lane) with apparent mo-
lecular weight of 48 kD. Glomerular supernatants from rabbits
with fibrin associated GN exhibited a marked increase in the
area of inhibitor activity (lane 2) compared to supernatants of
normal glomeruli (lane 1). Glomerular supernatants from rab-
bits with fibrin independent GN (lane 3) exhibited an area of
inhibitor activity similar to normal glomeruli.
Glomerular PA! activity
Supernatants from normal glomeruli contained 9.6 4.4
aU/105 glom of PA! activity (Table 4). Glomerular supernatants
from rabbits with fibrin associated GN contained higher PA!
activity (42.4 11.2 aU/105 glom) than normal glomerular
supernatants (P < 0.03). PAl activity was in glomerular super-
natants from rabbits with fibrin independent GN (0.8 0.8
aU/b5 gbom) was not significantly different from normals (P =
0.12). PAl activity was undetectable in glomerular lysates in all
groups.
Discussion
Autologous phase anti-GBM GN provides a model of fibrin
dependent GN which closely parallels crescentic human ON.
These diseases exhibit similar pathological features including
severe proliferative glomerular injury, macrophage infiltration,
crescent formation and fibrin deposition associated with aug-
mentation of glomerular tissue factor expression. In addition,
normal rabbit and human glomeruli exhibit similar profiles of
plasminogen activators and inhibitors [24, 28]. Thus, changes in
these molecules in this rabbit model of GN are likely to be
relevant to the human disease.
The current studies demonstrate a significant reduction in
GFA in association with fibrin deposition in ON. The release of
tPA and to a lesser extent uPA (demonstrated by fibrin autog-
raphy) into the conditioned medium of cultured glomeruli was
reduced. Urokinase activity, which was abundant in the mem-
brane fractions of glomeruli, was unaffected suggesting that this
pool of uPA may not have an important role in determining
glomerular fibrin deposition. Augmentation of PAl-i also con-
tributed to the reduction of GFA. Recent reports suggest that
up-regulation of PAl- 1 may also contribute to glomerular fibrin
deposition in human GN [291. These changes in plasminogen
activators and plasminogen activator inhibitors may act syner-
gistically with the augmentation of procoagulant activity to
enhance accumulation of fibrin in glomeruli and subsequent
injury in GN. By contrast in fibrin independent GN, glomerular
plasminogen activator production showed a tendency to in-
crease and PAI-l production was decreased.
A number of factors may contribute to the changes in
expression of pro- and anti-fibrinolytic molecules in glomeruli
of rabbits developing ON. The most striking among these
appears to be the cellular mediators of injury involved, in
particular, macrophages. In human GN, glomerular macro-
phage accumulation is associated with severe proliferative GN,
fibrin deposition and crescent formation [30]. Similarly, in
anti-GBM GN in rabbits, macrophage depletion prevents fibrin
deposition, crescent formation and augmentation of glomerular
procoagulant activity [10, 31]. The current studies demonstrate
an association between macrophage infiltration and down-
regulation of GFA, consistent with their role in initiating
giomerular fibrin deposition. Earlier studies by Stark, Miller
and Michael [32] suggest that similar down-regulation of OFA
may occur in association with fibrin deposition in chronic
immune complex ON in rabbits. A close correlation between
Mr uPA Dl D2 D3 El E2 E3 Fl F2 F3
50 lcD—
30 lcD —
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Fig. 2. Plasminogen activator activity demonstrated by fibrin autography in glomerular lysates (preabsorbed with normal goat serum) from a
normal rabbit (lane Dl), a rabbit with heterologous phase anti-GBM GN (lane El), and a rabbit with autologous phase anti-GBM GN (lane Fl).
The same lysates were preabsorbed with anti-tPA antibody (lanes D2, E2, F2) or anti-uPA antibody (lanes D3, E3, F3). Human uPA was run in
the left hand lane. Molecular weight calibrations are indicated.
Table 2. Tissue type plasminogen activator (tPA) activity and antigen
in glomerular supernatants and lysates of normal rabbits and rabbits
with anti-GBM GN
tPA activity
JUlIO5 glom
Supernatant Lysate
tPA antigen
ng/105 glom
Supernatant Lysate
Normal 8.7 3,7 UD 69.4 22.4 2.9 1.9
Fibrin 0.7 0.5a UD 17.7 ll.Ob 1.7 0.9
associated
GN
Fibrin 12.9 8.7 UD 99.0 22.3c 1.5 0.9
independent
GN
UD is undetectable.
a P < 0.08 c.f. NormalbP < 0.06 c.f. Normal
C P < 0.08 c.f. Normal
glomerular fibrin deposition, crescent formation and the inten-
sity of glomerular macrophage infiltration has also been dem-
onstrated in this immune complex model of ON [17].
It is possible that the changes in GFA may be a response to
glomerular inflammation unrelated to macrophage infiltraion.
To address this question, heterologous phase anti-GBM ON, in
which glomerular injury is independent of macrophages, was
Table 3. Urokinase (uPA) activity in glomerular supernatants and
lysates from normal rabbits and rabbits with anti-GBM GN
uPA activity JUlIO5 glom
Supernatant Lysate
Normal 6.7 1.3 132 14
Fibrin 6.5 1.8 95 12
associated
ON
Fibrin 16.8 1.2k 115 0.9
independent
GN
U P < 0.002 c.f. Normal
studied. Injury has previously been demonstrated to be depen-
dent on complement-induced neutrophil accumulation [33]
without significant glomerular fibrin deposition [10]. In this
model, the direction of change of OFA was opposite to that
seen with fibrin dependent ON, suggesting these changes are
not merely related to severity or duration of injury. Thus, the
changes in OFA are not uniform in all types of ON but may vary
according to the particular mediator systems involved. The
changes in glomerular fibrinolytic molecules observed in asso-
ciation with macrophages and fibrin deposition in this model of
ON may indicate a causal relationship.
Mr rhPAI-1 1 2
50 kO —
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Fig. 3. Plasminogen activator inhibitor
activity demonstrated by reverse fibrin
autography in glomerular supernatants from a
normal rabbit (lane I), a rabbit with
autologous phase anti-GBM GN (lane 2) and
a rabbit with heterologous phase anti-GBM
GN (lane 3). The left hand lane contains 50
kD recombinant human plasminogen activator
inhibitor type 1 (rhPAI-l).
Table 4. Plasminogen activator inhibitor (PAl) activity in glomerular
supernatants and lysates of normal rabbits and rabbits with anti-GBM
ON
PA! activity aU/1O glom
Supernatant Lysate
Normal 9.6 4.4 UD
Fibrin associated ON 42.4 11 .2 UD
Fibrin independent ON 0.8 08b UD
UD is undetectable.
a P < 0.03 c.f. Normal
b P < 0.003 c.f. Fibrin dependent GN
The mechanisms by which macrophages induce changes in
GFA are unknown. Macrophages have the capacity to produce
plasminogen activator inhibitors [34], and therefore may con-
tribute directly to the increase in PAl-i production in glomeruli.
Alternatively, macrophages may alter the expression of fibnno-
lytic molecules by intrinsic glomerular cells. Mesangial cells
produce tPA and PAl-i [35], and glomerular epithelial cells
produce tPA, uPA and PAl-i [36, 37] as do vascular endothelial
cells [38, 39]. In addition, macrophage cytokines such as
interleukin-l (IL-i) and tumor necrosis factor (TNF) can mod-
ulate the fibrinolytic activity of endothelial cells in a manner
favoring fibrin deposition [40]. These cytokines have also been
shown to alter the production of fibrinolytic molecules by
glomerular epithelial cells [36]. Moreover, production of IL-i
and TNF by glomerular macrophages has been previously
demonstrated in anti-GBM ON in rabbits [41, 42]. Thrombin
also has the potential to alter the expression of fibrinolytic
molecules by endothelial cells [43], mesangial cells [35] and
glomerular epithelial cells [37]. Thus, the capacity of macro-
phages to activate the coagulation cascade generating thrombin
provides a further mechanism by which macrophages may alter
GFA.
In summary, down-regulation of GFA is associated with
fibrin deposition and macrophage infiltration in anti-OBM ON
in rabbits. Both reduced tPA expression and increased PAI-l
contribute to down-regulation of GFA. Together with augmen-
tation of procoagulant activity, down-regulation of GFA ap-
pears to promote fibrin accumulation in this macrophage depen-
dent model of proliferative ON.
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